XTL Biopharmaceuticals Ltd ADR XTLB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if XTLB is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $2.56
- Day Range
- $2.35–2.49
- 52-Week Range
- $0.75–4.99
- Bid/Ask
- $2.33 / $2.88
- Market Cap
- $13.08 Mil
- Volume/Avg
- 6,198 / 828,043
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren’s syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.xtlbio.com
Valuation
|
Metric
|
XTLB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.58 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
XTLB
Financial Strength
|
Metric
|
XTLB
|
|---|---|
Quick Ratio | 13.62 |
Current Ratio | 14.09 |
Interest Coverage | −131.12 |
Quick Ratio
XTLB
Profitability
|
Metric
|
XTLB
|
|---|---|
Return on Assets (Normalized) | −23.23% |
Return on Equity (Normalized) | −24.47% |
Return on Invested Capital (Normalized) | −23.97% |
Return on Assets
XTLB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jvqwbtvcl | Hjvvl | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kylbzst | Cpbbh | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tbltnmw | Byhfnys | $97.8 Bil | |
MRNA
| Moderna Inc | Cnvhzbk | Dvxz | $38.8 Bil | |
ARGX
| argenx SE ADR | Hykdrgl | Lcysy | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Pvrjvnpxc | Npppv | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ywpbkwzg | Mgqplqf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pyfsrbf | Zcygfs | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tmmwrnyjsr | Qllwb | $12.5 Bil | |
INCY
| Incyte Corp | Sfpqzvq | Tlwmjg | $11.5 Bil |